Vectura Group
An inhaled product formulation, device design and development business offering an integrated inhaled drug delivery platform.
The UK-based company has 10 key inhaled and 11 non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development.
Its partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Dynavax and Tianjin KingYork.
Latest Vectura Group News & Features
13 August 2021
11 August 2021
9 August 2021
6 August 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze